Table of Contents
Metered‑dose cannabis inhalers are the first serious push to make inhaled cannabis look and behave like a pharmaceutical product instead of a lifestyle vape. For the CannabisTech crowd, they’re less a new gadget category and more a signal of where serious medical and tightly regulated markets are heading.
From “take a puff” to real dosing
For years, clinicians and regulators have made the same complaint: “Take 1–3 puffs as needed” is not a dose. Even with high‑end vaporizers, the amount of THC a patient actually inhales can swing wildly by device, batch, and how someone breathes or holds the vapor. That kind of variability makes cannabis hard to prescribe, hard to reimburse, and hard to plug into hospital protocols.
Metered‑dose cannabis inhalers (MDIs) borrow directly from the playbook of asthma and COPD inhalers. A standardized cannabis formulation is paired with a metering system so that each actuation delivers a defined dose with predictable pharmacokinetics. For regulators and payers who already live in the world of inhaler standards, this feels like familiar territory, not an experiment.
How metered‑dose cannabis inhalers work
Most cannabis MDIs share three core elements:
- A standardized formulation: either granulated, pharmaceutical‑grade cannabis flower or an EU‑GMP cannabinoid liquid.
- A metering mechanism: a valve, chip, or canister that dispenses a fixed volume or mass per actuation.
- A device body: the inhaler itself, which manages airflow, aerosolization, and in some cases temperature or power.
From that common base, two main architectures have emerged.
Flower‑based chips (SyqeAir)
Syqe’s platform uses Bedrocan‑produced flower that’s granulated and packed into sealed “VaporChips,” each preloaded with a precise micro‑dose of THC. Sixty chips sit in a cartridge that slides into the reusable SyqeAir electronic inhaler. The device punctures and vaporizes one chip at a time, and patients select their dose in micrograms using simple controls rather than guessing by “hits.”
Liquid‑based MDIs (Curaleaf / Jupiter and US brands)
In Europe, Curaleaf International and Jupiter Research use EU‑GMP cannabis extracts formulated into liquids and filled into sealed cartridges for a handheld, CE‑certified Class IIa inhaler. In US state markets, brands like Fairwinds and MÜV use pressurized canisters and plastic actuators that look and feel a lot like conventional asthma inhalers, delivering standardized THC or CBD doses with little to no visible vapor cloud.
In both approaches, “hit size” stops being a feel‑thing and becomes a design specification.
What the clinical data suggest
The obvious business question is whether all this extra engineering actually moves the needle on outcomes.
Early feasibility and pharmacokinetic work suggests that controlled, low‑dose inhalation can deliver meaningful analgesia at much lower THC exposures than typical smoking or ad‑lib vaping. Studies with the Syqe–Bedrocan platform report dose‑dependent pain relief and predictable plasma THC curves, using microgram‑level doses that sit well below what many chronic patients self‑administer with pipes or standard vapes.
Longer‑term observational data in chronic pain and other indications show a pattern: adverse events cluster during initial titration, then drop off once patients settle into an individualized dose. Many patients keep or improve symptom control while using substantially less THC than in their previous regimens.
For hospital pharmacists and payers, that reads like a familiar value proposition: lower total cannabinoid exposure, more predictable kinetics, and a cleaner clinical story than combusted flower. For operators, it’s a working example of how inhaled products can actually meet medical‑grade expectations instead of just talking about it.
Who is actually shipping products?
A few concrete implementations make this feel less theoretical.
Syqe Medical – flower‑based, chip‑style inhaler
Syqe’s SyqeAir is often held up as the reference point for a true medical cannabis inhaler built around flower. Each cartridge holds 60 sealed VaporChips of processed Bedrocan cannabis, and the electronic inhaler manages temperature, airflow, and dose selection. The platform is backed by pharmacokinetic data, safety work, and long‑term observational studies, giving clinicians and regulators something that looks and reads much closer to a classic drug‑device dossier.
Curaleaf International / Jupiter – CE‑certified liquid inhaler
Curaleaf International, together with Jupiter, has EU medical device certification on a handheld liquid cannabis inhaler that’s been described as Europe’s first CE‑certified liquid medical cannabis inhaler. Classified as a Class IIa device under EU MDR 2017/745, it uses EU‑GMP cannabinoid formulations in proprietary cartridges and is designed for controlled dosing under prescription in markets like the UK. Strategically, it moves Curaleaf upstream—beyond flower and oil—into the role of device company with medical‑grade hardware and regulatory assets.
US state‑level MDIs – consumer‑regulated, medically inspired
In US legal states, metered‑dose THC inhalers from brands such as Fairwinds and MÜV pair pressurized canisters with actuators that mimic classic MDIs. They’re treated as cannabis products, not formal medical devices, but they clearly speak to demand from older and health‑focused consumers for smoke‑free, discreet, metered inhalation. They also act as a testing ground for language, packaging, and user experience that more regulated programs can build on.
What this means for the cannabis industry
From the perspective of ministries of health, hospital committees, and insurers, MDIs check boxes that generic vaporizers usually miss.
- They map cleanly onto existing inhaler frameworks, with expectations around dose uniformity, device reliability, and quality systems. A cannabis product that can be evaluated with the same mental model as other inhalers is far easier to assess than an open‑system vape with an unknown delivered dose.
- They support a credible individualized titration story. Bedrocan and Syqe, for example, highlight the ability to titrate patients down to the lowest effective THC dose, cutting exposure and side effects while keeping symptom control. This means fewer products, fewer adverse events, and better documentation for payers.
- They make formulary and hospital integration more realistic. A CE‑marked Class IIa device with EU‑GMP inputs and supporting data fits naturally into tenders and formularies in a way a jar of flower plus a consumer vaporizer simply doesn’t.
Where the opportunity (and friction) lies
For CannabisTech readers, the opportunity set looks something like this:
- Cultivators and extractors: supply inhaler‑grade inputs to existing device platforms (flower for chip systems, extracts for liquid MDIs) under EU‑GMP and similar standards.
- Device and OEM players: design and manufacture inhaler bodies, valves, and cartridges under medical‑device quality systems, then partner with cannabis companies on co‑branded platforms.
- Data‑driven brands and MSOs: sponsor and own clinical or real‑world evidence around specific MDI products, giving them real leverage in payer and policymaker conversations.
The friction is just as real:
- Device development, certification, and QA make these efforts feel much more like med‑device programs than standard vape launches.
- SKU diversity is narrow for now; MDIs tend to stick with a small set of chemotypes and ratios instead of chasing constant “new strain” churn.
- Clinician and patient education is still a choke point, with many people defaulting to smoking, edibles, or generic vapes out of habit and familiarity.
MDIs are not going to wipe every cartridge or dry‑herb vape off dispensary shelves. But in markets where cannabis is expected to behave like conventional medicine in tightly regulated medical frameworks, they are strong candidates to become the default inhaled option. The operators who understand that shift early and build capabilities around devices, EU‑GMP inputs, and data will be best positioned as the medical side of the cannabis industry matures.
